VIDEO: White blood cell count correlates with thrombotic risk in polycythemia vera
Click Here to Manage Email Alerts
In this video, Aaron T. Gerds, MD, MS, discusses critical takeaways from the REVEAL study presented at ASH Annual Meeting and Exposition.
The longitudinal, real-world, prospective, observational study analyzed blood counts — including red blood cell, white blood cell, and platelet — and thrombotic risk among patients with polycythemia vera.
“Not only controlling the hematocrit is important in reducing thrombotic risk, but it can also be concluded that if we can control white blood cell counts, and possibly platelet counts, we may further reduce the risk of thrombosis in those highest risk patients,” said Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute and medical director of Case Comprehensive Cancer Center.
Reference
- Gerds AT, et al. Abstract 239. Presented at: ASH Annual Meeting & Exposition; Dec. 11-14, 2021; Atlanta.
Collapse
Healio Interview
Click Here to Manage Email Alerts